8-methyl-1,3,6-trichlorodibenzofuran | 172485-96-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 英文名称: 8-methyl-1,3,6-trichlorodibenzofuran
• 英文别名: Dibenzofuran, 1,3,6-trichloro-8-methyl-；1,3,6-trichloro-8-methyldibenzofuran
• CAS: 172485-96-0
• 化学式: C₁₃H₇Cl₃O
• 分子量: 285.557
• InChiKey: GMEQDJYQPZMHRI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.1
• 重原子数：
  17
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  13.1
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• ITE for cancer intervention and eradication
  申请人：Ariagen, Inc.

  公开号：US10195182B2

  公开（公告）日：2019-02-05

  A method of cancer intervention or eradication by administering an effective amount of an endogenous ligand for the aryl hydrocarbon (Ah) receptor (AhR) named ITE or one of its analogs (the active ingredient) to a subject with cancer is disclosed. An effective dose and dosing frequency of the active ingredient are determined by measuring its blood levels of the subject after dosing. The active ingredient formulated with a carrier system is applied topically, enterally, or parenterally to the subject. The formulated drug can also be administered together with one or more of other cancer therapeutic agents. A maintenance dosing is provided after the subject is free of cancer to insure the cancer eradication. Subjects with cancers of prostate, liver, lung, ovarian, and breast are preferably accepted for treatment.

  本发明公开了一种癌症干预或根除方法，即给癌症患者服用有效量的芳基烃（Ah）受体（AhR）内源配体 ITE 或其类似物之一（活性成分）。活性成分的有效剂量和给药频率是通过测量给药后受试者的血药浓度确定的。与载体系统配制的活性成分可局部、肠道或胃肠道给药。配制好的药物还可以与一种或多种其他癌症治疗药物一起使用。受试者痊愈后，还需继续用药，以确保根除癌症。前列腺癌、肝癌、肺癌、卵巢癌和乳腺癌患者最好接受治疗。
• Methods of cancer treatment with 2-(1′H-Indole-3′-carbonyl)-thiazole-4-carboxylic acid methyl ester
  申请人：Ariagen, Inc.

  公开号：US10632106B2

  公开（公告）日：2020-04-28

  Provided herein are methods of cancer treatment by administering an effective amount of an endogenous ligand for the aryl hydrocarbon (Ah) receptor (AhR) named ITE or one of its structural analogs to a patient with cancer, for example, prostate, liver, lung, ovarian, breast, skin, colon (or rectum), stomach, pancreatic, kidney, bladder, soft tissue, or cervical cancer.

  本文提供的癌症治疗方法是给癌症患者施用有效量的芳基烃（Ah）受体（AhR）内源配体 ITE 或其结构类似物之一，例如前列腺癌、肝癌、肺癌、卵巢癌、乳腺癌、皮肤癌、结肠癌（或直肠癌）、胃癌、胰腺癌、肾癌、膀胱癌、软组织癌或宫颈癌。
• Alkyl PCDF as a treatment for prostate cancer
  申请人：Safe H. Stephen

  公开号：US20050143450A1

  公开（公告）日：2005-06-30

  The present invention is directed to a method of modulating a prostate neoplasm by administering an alkyl-substituted PCDF.

  本发明涉及一种通过施用烷基取代的 PCDF 来调节前列腺肿瘤的方法。
• ENDOCRINE THERAPY FOR BREAST CANCER: COMBINED TREATMENT WITH TAMOXIFEN PLUS ALKYL PCDFS
  申请人：THE TEXAS A&M UNIVERSITY SYSTEM

  公开号：EP1140047A2

  公开（公告）日：2001-10-10
• ALKYL-SUBSTITUTED PCDF AS A TREATMENT FOR PROSTATE CANCER
  申请人：THE TEXAS A & M UNIVERSITY SYSTEM

  公开号：EP1608306A2

  公开（公告）日：2005-12-28